Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention

Chang-jiang Ge; Fei Yuan; Li-xia Feng; Shu-zheng Lv; Hong Liu; Xian-tao Song; Xin Chen; Yong Huo

doi:10.1007/s11655-013-1580-x

Your Location：

Home >

Browse articles >

Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention

Updated：2021-08-27

- Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention
- Chinese Journal of Integrative Medicine Vol. 20, Issue 2, Pages: 88-93(2014)
- Affiliations：
  
  1. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,Beijing,China
  2. Department of Cardiology, Peking University First Hospital,Beijing,China
- Author bio：
- Funds：
  
  Supported by the Key Projects in the National Science and Technology Pillar Program during 11th Five-Year Plan Period (No. 2006BAI01A02);the Capital Medical Development Fund (No. SF-2009-I-09);and the President of Science and Technology Development Fund of Beijing Anzhen Hospital (No. 2013F01)
- DOI：10.1007/s11655-013-1580-x
  CLC：
- Published：2014，
  
  Published Online：13 December 2013，
Scan for full text
Ge, Cj., Yuan, F., Feng, Lx. et al. Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention., Chin. J. Integr. Med. 20, 88–93 (2014). https://doi.org/10.1007/s11655-013-1580-x

Chang-jiang Ge, Fei Yuan, Li-xia Feng, et al. Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention. [J]. Chinese Journal of Integrative Medicine 20(2):88-93(2014)
Ge, Cj., Yuan, F., Feng, Lx. et al. Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention., Chin. J. Integr. Med. 20, 88–93 (2014). https://doi.org/10.1007/s11655-013-1580-x DOI：

Chang-jiang Ge, Fei Yuan, Li-xia Feng, et al. Clinical effect of Maixuekang Capsule (脉血康胶囊) on long-term prognosis in patients with acute coronary syndrome after percutaneous coronary intervention. [J]. Chinese Journal of Integrative Medicine 20(2):88-93(2014) DOI： 10.1007/s11655-013-1580-x.

摘要

To study the changes of adenosine diphosphate (ADP)-induced platelet aggregation rate

and evaluate the effects of Maixuekang Capsule (脉血康胶囊

MKC) on platelet aggregation rate and long-term prognosis of patients with acute coronary syndrome after percutaneous coronary intervention (PCI). A total of 236 patients with acute coronary syndrome

who received successful PCI

were randomly assigned to a trial group (116 cases) and a control group (120 cases) according to random numbers; treatment allocation occurred when the participants met the inclusion criteria and signed the informed consent forms. In the trial group

the patients were treated with MKC combined with routine medication

and in the control group the patients were treated with routine medication. The therapeutic course for the two groups was 12 months and the follow-up was 12 months. The levels of ADP-induced platelet aggregation rate and serum high-sensitive C-reactive protein (hs-CRP) were determined before PCI

12 h and 30 days after PCI. In the meantime

the incidence of cardio-/cerebrovascular events was recorded during the 12-month follow-up. Compared with before PCI

the levels of ADP-induced platelet aggregation rate and serum hs-CRP were significantly higher at 12 h after PCI (P<0.05). They were significantly reduced after 30-day-treatment of MKC

showing statistical differences when compared with those in the control group (P<0.05). During the 12-month follow-up

the incidence of cardio-/cerebrovascular events was significantly lower in the trial group than in the control group (6.9% vs. 12.5%

P<0.01). ADP-induced platelet aggregation function was significantly elevated after PCI. MKC improved the prognosis of patients with acute coronary syndrome

possibly through inhibiting the platelet aggregation

fighting against inflammation

and protecting the vascular endothelial function.

Abstract

To study the changes of adenosine diphosphate (ADP)-induced platelet aggregation rate

and evaluate the effects of Maixuekang Capsule (脉血康胶囊

MKC) on platelet aggregation rate and long-term prognosis of patients with acute coronary syndrome after percutaneous coronary intervention (PCI). A total of 236 patients with acute coronary syndrome

who received successful PCI

the patients were treated with MKC combined with routine medication

12 h and 30 days after PCI. In the meantime

the incidence of cardio-/cerebrovascular events was recorded during the 12-month follow-up. Compared with before PCI

the levels of ADP-induced platelet aggregation rate and serum hs-CRP were significantly higher at 12 h after PCI (P<0.05). They were significantly reduced after 30-day-treatment of MKC

showing statistical differences when compared with those in the control group (P<0.05). During the 12-month follow-up

the incidence of cardio-/cerebrovascular events was significantly lower in the trial group than in the control group (6.9% vs. 12.5%

P<0.01). ADP-induced platelet aggregation function was significantly elevated after PCI. MKC improved the prognosis of patients with acute coronary syndrome

possibly through inhibiting the platelet aggregation

fighting against inflammation

and protecting the vascular endothelial function.

关键词

acute coronary syndromeplatelet aggregation inhibitorsPercutaneous Coronary InterventionMaixuekang Capsule

Keywords

acute coronary syndromeplatelet aggregation inhibitorsPercutaneous Coronary InterventionMaixuekang Capsule

references

Lin Y, Song XT, Meng K, Tian R, Yuan F, Chen X, et al. Analysis and evaluation of stent thrombosis induced acute coronary syndrome after drug eluting stent deployment. J Cardiovasc Pulmon Dis (Chin) 2008;27:144–147.

Xue M, Yin HJ, Wu CF, Ma XJ, Guo CY, Huang Y, et al. Effect of Chinese drugs for activating blood circulation and detoxifying on indices of thrombosis, inflammatory reaction, and tissue damage in a rabbit model of toxin-heat and blood stasis syndrome. Chin J Integr Med 2013;19:42–47.

Chen KJ, Shi DZ, Xu H, LÜ SZ, Li TC, Ke YN, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J 2006;119:6–13.

Miu YX. Clinical observation of Maixuekang Capsule treatment on 60 people who has angina. Guangxi Med J (Chin) 2008;30:661–662.

Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2007;50:e1–e157.

Committee of Cardiovascular Disease, Chinese Association of Integrated Traditional Chinese and Western Medicine. Standard of syndrome differentiation of coronary heart disease in Chinese medicine. Chin J Integr Tradit West Med (Chin) 1991;11:257.

Wang J, Chen KJ, Weng WL, Qian ZH, Wang Y, Liu JG, et al. Research on the diagnostic criteria of blood-stasis symptom-complex. Chin J Integr Tradit West Med (Chin) 1988;10:580–585.

Hamon M. Mechanism of thrombosis: physiopathology, role of thrombin and its inhibition by modern therapies. Arch Mal Coeur Vaiss 2006;99:5–9.

Meng BB, LÜ CZ, Jiang YY. Direct Thrombin inhibitors and the application of them in cardiovascular disease. Chin J Cardiovasc Rev (Chin) 2006;4:72–75.

Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126–2130.

Gao LJ, Chen J, Chen JL. The pathophysiological mechanism and clinical research progress of coronary artery stent thrombosis. Chin Circulat J (Chin) 2007;22:396–398.

Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:647–654.

Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004;109:3064–3067.

Wenaweser P, Hess O. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;46:CS5–CS6.

Wang D, Paria BC, Zhang Q, Karpurapu M, Li Q, Gerthoffer WT, et al. A role for Gab1/SHP2 in thrombin activation of PAK1: gene transfer of kinase-dead PAK1 inhibits injuryinduced restenosis. Circ Res 2009;104:1066–1075.

Jormalainen M, Vento AE, Lukkarinen H, Kääpä P, Kytö V, Lauronen J, et al. Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2007;21:224–231.

Mo W, Zhang YL, Chen HS, Wang LS, Song HY. A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition. J Thromb Thrombolysis 2009;28:230–237.

FULL TEXT LINK

More>

Views

763

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Protective effect of Chinese herbs for supplementing qi, nourishing yin and activating blood circulation on heart function of patients with acute coronary syndrome after percutaneous coronary intervention

Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial

Summary of 2011 Integrative Medical Doctors Conference

Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy

A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule (芎芍胶囊) in preventing restenosis after percutaneous coronary intervention: A subgroup analysis of senile patients

Related Author

No data

Related Institution

Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University

Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Gastroenterology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Institute of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Guangdong Provincial Hospital of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰